- WKN: A0LD6E
- ISIN: DE000A0LD6E6
- Land: Deutschland
Nachricht vom 13.10.2020 | 07:00
Gerresheimer AG: Gerresheimer on track for strong second half-year
DGAP-News: Gerresheimer AG
/ Key word(s): Quarter Results/9 Month figures
- Third quarter on schedule
- Group revenues EUR 349m; 2.1% organic revenue growth in core business
- Adjusted EBITDA increases by 4.1% to EUR 75m
- Significant improvement in free cash flow to EUR 38m
- Strong fourth quarter 2020 expected
- Guidance for 2020 confirmed
Duesseldorf, October 13, 2020-Gerresheimer AG delivered profitable growth in its core business in the third quarter of 2020 and confirmed its guidance for 2020 despite temporarily lower demand for high-quality perfume flacons due to Covid-19. "We are working together with vaccine manufacturers to prepare for the global Covid-19 vaccination campaigns. For this purpose, we are building additional capacity for the production of injection vials. Beyond this, there are numerous growth opportunities for us. And we are consequently implementing our strategy for profitable and sustainable growth. We are investing in our Company's future, growing profitably and expect a strong fourth quarter," said Dietmar Siemssen, CEO of Gerresheimer AG.
On the basis of 2.1% organic growth in its core business, Gerresheimer generated revenues of EUR 349m in the third quarter of the financial year 2020 (June 1 to August 31, 2020). Gerresheimer achieved profitable growth with its glass and plastic primary packaging for liquid and solid drugs, syringes and drug delivery devices such as insulin pens and asthma inhalers. The injection vials produced by Gerresheimer will be an important part of the forthcoming Covid-19 vaccination campaigns, for which Gerresheimer is preparing together with vaccine manufacturers. Gerresheimer continues to invest in additional capacity in this side of the business. Demand for high-quality perfume flacons was down in the last few quarters relative to the prior year due to Covid-19. In the latest quarter, Gerresheimer has been able to offset the lower revenues from cosmetics packaging with higher revenues from drug packaging and drug delivery devices.
The third quarter of 2020 saw an increase in the adjusted EBITDA by 4.1% to EUR 75m. The adjusted EBITDA margin stood at 21.5%. Adjusted net income came to EUR 31m in the third quarter of 2020. Third-quarter 2020 adjusted earnings per share after non-controlling interests amounted to EUR 0.97. Free cash flow in the third quarter was strong amounting to EUR 38m. Adjusted EBITDA leverage was unchanged at 3.2x as of the end of the third quarter of 2020. At the beginning of October, Gerresheimer signed an agreement for a EUR 325m promissory loan on attractive terms. The funds are mainly being used to refinance the five-year promissory loan from 2015. Completion is scheduled for November 10, 2020.
Guidance for 2020
- Revenue growth in the mid-single digit percentage range
- Adjusted EBITDA margin of around 21%
- Capital expenditure amounting to roughly 12% of revenues
Indications for subsequent years
- Annual organic revenue growth in the mid-single digit percentage range
- Targeted medium-term adjusted EBITDA margin of 23%
- Annual capital expenditure of between 8% and 10% of revenues
The quarterly statement for the third quarter of 2020 is available here:
Investor Relations contact
1 Adjusted EBITDA: Net income before income taxes, net finance expense, amortization/impairment losses of fair value adjustments, depreciation and amortization, impairment losses, restructuring expenses, and one-off income and expenses.
2 Adjusted net income: Net income before amortization/impairment losses of fair value adjustments, restructuring expenses, portfolio adjustments, the balance of one-off income and expenses, and the related tax effects.
3 Adjusted net income per share after non-controlling interests divided by 31.4m shares.
4 Adjusted EBITDA leverage: The relation of net financial debt to adjusted EBITDA of the last twelve months according to the credit agreement currently in place.
5 The change has been calculated on a EUR k basis.
6 Without the changeover effects from the accounting standard IFRS 16 'Leases', which will be applicable for us from December 1, 2019.
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1140426|
|End of News||DGAP News Service|
Der spezialisierte „Bondpicker“: Deutscher Mittelstandsanleihen Fonds
Der offene Rentenfonds investiert hauptsächlich in ausgewählte Anleihen von Unternehmen des deutschen Mittelstands. Das Kernstück des Investment-Ansatzes ist das KFM-Scoring-Modell, das speziell für diesen Mittelstandssektor entwickelt wurde. Durch das sehr erfahrene aktive Fondsmanagement und den bewährten Anlagestil, sollte dem Anleihefonds auch zukünftig eine deutliche Outperformance gegenüber der allgemeinen Entwicklung am Mittelstandsanleihenmarkt gelingen.
Der AKTIONÄR News
15. Januar 20:17 Grüne Raketen – wer profitiert vom Green New Deal?
15. Januar 18:59 Palantir: Neue Fantasie dank Joe Biden
15. Januar 16:51 Evotec: Kurz durchatmen
News im Fokus
SAP SE: SAP veröffentlicht vorläufige Ergebnisse für das vierte Quartal 2020 sowie Ausblick für 2021
14. Januar 2021, 23:35
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Hinzufügen Valneva SE
15. Januar 2021